ArticleNPJ Parkinson's disease2022
Biomarker characterization of clinical subtypes of Parkinson Disease.
Article in NPJ Parkinson's disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association between the risk and severity of Parkinson's disease and plasma homocysteine, vitamin B12 and folate levels: a systematic review and meta-analysis.Frontiers in aging neuroscience · 2023Pooled it
- AMPLITUDE PERFORMANCE SUBTYPES IN PARKINSON'S DISEASE.medRxiv : the preprint server for health sciences · 2026Article
- The Role of Vitamin D in Parkinson's Disease: Evidence from Serum Concentrations, Supplementation, andNeuroSci · 2025Review
- Correlation of inflammatory markers with depression and sleep disorders accompanying the prodromal stage of Parkinson's disease.World journal of psychiatry · 2025Review
- Review
- Identifying subtypes of longitudinal motor symptom severity trajectories in early Parkinson's disease patients.Frontiers in neurology · 2025Article
- Emerging Biomarkers in Metabolomics: Advancements in Precision Health and Disease Diagnosis.International journal of molecular sciences · 2024Review
- Bidirectional relationship between olfaction and Parkinson's disease.NPJ Parkinson's disease · 2024Article
- Machine Learning for Early Detection of Cognitive Decline in Parkinson's Disease Using Multimodal Biomarker and Clinical Data.Biomedicines · 2024Article
- Neurotoxicology of dopamine: Victim or assailant?Neurotoxicology · 2024Review
- How Lifetime Evolution of Parkinson's Disease Could Shape Clinical Trial Design: A Shared Patient-Clinician Viewpoint.Brain sciences · 2024Article
- The severity assessment of Parkinson's disease based on plasma inflammatory factors and third ventricle width by transcranial sonography.CNS neuroscience & therapeutics · 2024Article
- Disease Progression of Data-Driven Subtypes of Parkinson's Disease: 5-Year Longitudinal Study from the Early Parkinson's Disease Longitudinal Singapore (PALS) Cohort.Journal of Parkinson's disease · 2024Article
- Synaptic Vesicle Glycoprotein 2C: a role in Parkinson's disease.Frontiers in cellular neuroscience · 2024Review
- Microstructural alterations in white matter and related neurobiology based on the new clinical subtypes of Parkinson's disease.Frontiers in neuroscience · 2024Article
- Chaudhuri's Dashboard of Vitals in Parkinson's syndrome: an unmet need underpinned by real life clinical tests.Frontiers in neurology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The biological underpinnings of the PD clusters remain unknown as the existing PD clusters lacks biomarker characterization. We try to identify clinical subtypes of Parkinson Disease (PD) in an Asian cohort and characterize them by comparing clinical assessments, genetic status and blood biochemical markers. A total of 206 PD patients were included from a multi-centre Asian cohort. Hierarchical clustering was performed to generate PD subtypes. Clinical and biological characterization of the subtypes were performed by comparing clinical assessments, allelic distributions of Asian related PD gene (SNCA, LRRK2, Park16, ITPKB, SV2C) and blood biochemical markers. Hierarchical clustering method identified three clusters: cluster A (severe subtype in motor, non-motor and cognitive domains), cluster B (intermediate subtype with cognitive impairment and mild non-motor symptoms) and cluster C (mild subtype and young age of onset). The three clusters had significantly different allele frequencies in two SNPs (Park16 rs6679073 A allele carriers in cluster A B C: 67%, 74%, 89%, p = 0.015; SV2C rs246814 T allele distribution: 7%, 12%, 25%, p = 0.026). Serum homocysteine (Hcy) and C-reactive protein (CRP) levels were also significantly different among three clusters (Mean levels of Hcy and CRP among cluster A B C were: 19.4 ± 4.2, 18.4 ± 5.7, 15.6 ± 5.6, adjusted p = 0.005; 2.5 ± 5.0, 1.5 ± 2.4, 0.9 ± 2.1, adjusted p < 0.0001, respectively). Of the 3 subtypes identified amongst early PD patients, the severe subtype was associated with significantly lower frequency of Park16 and SV2C alleles and higher levels of Hcy and CRP. These biomarkers may be useful to stratify PD subtypes and identify more severe subtypes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.